On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane
Open accessThe DOI matches its Crossref record.
Abstract
The carrying out in the Bio-Chemical Laboratory of the experiments otn the secretion of organic acids in diabetes described in the previous paper supplied an opportuniity for testing the hypothesis that the internal secretion of the pancreas might be stimulated and initiated (similarly to the externial secretion) by a substance of the nature of a hormone or secretin yielded by the duodenal mucous membrane ; and that in certain cases of diabetes the appearance of sugar in the urine might be due to funictional disturbance occasioned by the absence of such an intestinial excitanit of the initernal secretion.The fact that an internal secretion of the pancreas is niecessary for the regulation of carbohydrate metabolism, and that in the absence of this secretion oxidation of dextrose canniot be carried out, with the result that death occurs from acute diabetes, has been clearly proven by the experimenits of Minkowski and v. Mering,; and others on complete and partial panicreas removal, and the history of the subject is too well-known to require detailed description here.It was suggested by Schafer that the formation of the internal pancreatic secretion might possibly bc due to peculiar nests of cells of different form and staining properties to the other secreting cells of the gland.These cells from their isolated appearanice, and after the name of the observer who first described them, are called the 'islets of Langerhans.'
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gut-hormone derived GIP, secreted from enteroendocrine K-cells in the upper intestine in the duodenum and jejunum mucosae32, was initially discovered to play an integral role in the body’s response to glucose intake33,34 (Textbox).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [32]
Citations
Cited by
Items 201–278 of 278
Khalimov, Y. S., & Kuzmich, V. G. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-21-189-197 · Cited by 2
Diabetes Mellitus - A Membrane Receptor Defect
Donnelly, P. E., & Turtle, J. R. (1974) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1974.tb03180.x · Cited by 2
Brown, J. C. (1988) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(88)80037-5 · Cited by 4
I fattori intestinali della secrezione insulinica con particolare riguardo al ruolo del glucagone
Brunetti, P., & Marri, G. (1968) · Acta Diabetologica · doi:10.1007/bf01545356 · Cited by 2
Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR)
Chandarana, R. C., D’Souza, J. S., & Coutinho, E. C. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0461-4_116 · Cited by 2
Kahal, H. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 2
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.01.001 · Cited by 1
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
Glucagon-like peptide 1 receptor agonists: anti-inflammatory effects in cardiovascular diseases
Bajić, Z., Šobot, T., Stojiljković, M. P., Djuric, D. M., & Škrbić, R. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0021 · Cited by 1
Yoder, S. M. (2010) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Bedeutung von GLP‐1 für die Glucose‐Homöostase. Entdeckung der Inkretine
Blume, H. H., Wedemeyer, R., & Gallwitz, B. (2010) · Pharmazie in unserer Zeit · doi:10.1002/pauz.201000356 · Cited by 1
A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus
Samat, A., Bhargava, A., & Reddy, V. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3489 · Cited by 2
Carcinogenesis and endocrine pancreas deficiency, a working frame for cancer prevention or treatment
Israël, M. (2015) · International Journal of Cancer and Oncology · doi:10.15436/2377-0902.15.011 · Cited by 1
“Following the works of Bayliss and Starling on secretin[12] and the observation of Moore[13] on the glucose lowering effect of gut extracts, incretins were purified[14].”
Саприна, Т. В., Timokhina, Y. S., Мусина, Н. Н., Prokhorenko, T. S., Таширева, Л. А., & Goncharevich, O. K. (2013) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2013-3-132-147 · Cited by 2
Four sidenotes about glucagon peptides
Rehfeld, J. F. (2022) · Peptides · doi:10.1016/j.peptides.2022.170924 · Cited by 1
Incretin physiology in health and disease
Meier, J. J., & Nauck, M. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch11 · Cited by 1
Gut as an Endocrine Organ: The Role of Nutrient Sensing in Energy Metabolism
Wang, M. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch1 · Cited by 1
Gastric Inhibitory Polypeptide (GIP): a Therapeutic Possibility?
MOODY, A. J., Jones, I. R., Krarup, T., Owens, D. R., & Saurbrey, N. (1985) · Acta Paediatrica · doi:10.1111/j.1651-2227.1985.tb10141.x · Cited by 1
Recent research developments in diabetes mellitus. 3.
SHARKEY, T. P. (1966) · PubMed · Cited by 1
Editorial: Gastrointestinal Hormones
Paternoster, S., Keating, D. J., & Falasca, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00498 · Cited by 1
“After more than a century since the first description in 1906 of metabolically active gut extracts by Moore (1), we are still unveiling novel functions in health and disease for this complex endocrine organ.”
BackgroundAthanasia, K., Marina, S., & Stavros, I. (2011) · InTech eBooks · doi:10.5772/20616
The binding and activation of the glucagon-like peptide-1 receptor by exendin-4
Nasr, E. M. N. (2010) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Ramesh, N. (2015) · University Library - University of Saskatchewan (University of Saskatchewan)
McIntyre, N. (1978) · Novartis Foundation symposium · doi:10.1002/9780470720363.ch8
Morettini, M. (2012) · Università Politecnica delle Marche (Università Politecnica delle Marche)
Islet Amyloid Polypeptide/GLP‐1/Exendin
Baggio, L. L., & Drucker, D. J. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0209
Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus
Bhargava, A. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1055251
“This phenomenon, known as the incretin effect, is responsible for over half of the insulin release that occurs following a carbohydrate load [3,4].”
BackgroundBehavior of the organs of the digestive system
Pk, K. (1984) · Neuroscience and Behavioral Physiology · doi:10.1007/bf01149620 · Cited by 1
ADI-AMD recommendations on insulin treatment during artificial nutrition
Fatati, G., Cortinovis, F., Fontana, L., Fusco, M. A., Leotta, S., Marelli, G., Mirri, E., Parillo, M., Sukkar, S. G., Tagliaferri, M., et al. (2010) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1007/s12349-009-0073-0 · Cited by 1
Adolescent type 1 diabetes : Eating and gastrointestinal function
Lodefalk, M. (2009) · DiVA (Digitala Vetenskapliga Arkivet)
The role of incretin peptides and ghrelin in upper gut motility and metabolic control
Edholm, T. (2006) · Figshare
Herzig, K., Otte, J., & Fölsch, U. R. (1999) · Springer eBooks · doi:10.1007/978-3-642-59960-6_58
Olver, A. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0101080
Widenmaier, S. B. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071070
“Soon after the discovery of secretin it was predicted that gastrointestinal hormones could regulate “internal secretions” of the pancreas and have important effects on glucose homeostasis (Moore, 1906).”
BackgroundHalimi, S. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70857-0
“[3] Moore B.”
BackgroundPaulo, S., & Girardi, C. (2015)
The Role of Incretins in Insulin Secretion
Salehi, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_4-1
正常, 肥満, 糖尿病および肝硬変症におけるEntero-Insular Axisの検討
楢崎, 健., 稙田, 太., 小野, 弘., 井口, 登., 渡辺, 淳., 迫, 康., Umeda, F., & 井林, 博. (1985) · 糖尿病 · doi:10.11213/tonyobyo1958.28.1105
Jenkins, A. L. (2005) · University of Surrey Open Research repository
INTESTINAL PEPTIDES AND ETHNIC DIFFERENCES IN INSULIN SECRETION
Higgins, P. B., Fernandez, J. R., Ph., D., D, J. A. M., Clancy, J. P., Garvey, W. T., & Higgins, P. B. (2006)
GI Peptides, Energy Balance, and Cancer
Bruno, D. S., & Wolfe, M. M. (2016) · Energy balance and cancer · doi:10.1007/978-3-319-41677-9_11
Non‐Insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Jorsal, T., & Knop, F. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch32
Wood, S. M. (1984) · Springer eBooks · doi:10.1007/978-1-4684-4853-5_17
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Gajjar, A. K., & Pathak, C. D. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220103124013
Historical Background of Diabetic Kidney Disease
Fonseca, V. A., Bhatnagar, A., & Chamarthi, G. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_1
Welcome, M. O. (2018) · Springer eBooks · doi:10.1007/978-3-319-91056-7_8
The Role of Incretins in Insulin Secretion
Salehi, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_4
Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR)
Chandarana, R. C., D’Souza, J. S., & Coutinho, E. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_116
Mazzaferri, E. L. (1979) · World Journal of Surgery · doi:10.1007/bf01654759
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Sitagliptin: the fixed combination of the first dipeptidyl peptidase 4 inhibitor and metformin
Egshatyan, L. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-168 · Cited by 2
(2023) · Wiley eBooks · doi:10.1002/9781394236329.refs
Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
Nauck, M. A. (2023) · Deutsches Ärzteblatt · doi:10.3238/persdia.2023.11.03.01
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
The entero-insular axis and metabolic syndrome
Sarkar, J., & Chakrabarti, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00047-5
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, J., Liu, Y., & Jia, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0417
Predators and the evolution of obesity in humans
Carr, J. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29218-7.00005-5
Buchanan, K. D. (1992) · Developments in cardiovascular medicine · doi:10.1007/978-94-011-2734-9_2
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.12.005 · Cited by 1
Histoire des incrétines GLP-1/GIP – De l’hormone au médicament couteau-suisse
Portha, B. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026005
Pharmacological management of obesity: Current landscape and emerging therapies
Atal, S., Agrawal, C., Gupta, R., & Sadasivam, B. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_37_26
“[18] This concept was formally named in 1929 when Zunn and LaBarre introduced the term “incretin” to describe molecules released from the gut that increase pancreatic endocrine activity.”
Physiology and therapeutic insights of incretins in 2026: An update
Hirlemann, M., Phan, A., Carette, C., Beyec, J. L., Ledoux, S., & Gall, M. L. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.08.106
More than just adipose: the impact of GLP1RA on lean tissue
Julien, M., Jeromson, S., & Wright, D. C. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.90062.2026
Glucagon-like Peptide-1 Receptor Agonists Promote Sympathetic Innervation in Mouse Adipose Tissues
Fu, K., Deng, Z., Wu, W., Yang, J. H., & Cao, Y. (2026) · Metabolites · doi:10.3390/metabo16110813
The role of carbohydrate and oral agents in the treatment of diabetes mellitus.
Odell, W. D. (1973) · PubMed Central
Metadata
- Authors
- Moore, B., Edie, E. S., & Abram, J. H.
- Affiliations
- University of Liverpool (GB)
- Carnegie Research Scholar
- Royal Infirmary, Liverpool
- ORCID
- Moore, Benjamin
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 1906-01-01
- Volume
- 1
- Issue
- 1
- Pages
- 28-38
- ISSN
- 0306-3283 (ISSN-L)
- PMC
- PMC1276119
- OpenAlex
- W2107757312
- Cited by
- 279
- References
- 0
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 4 · 2020: 4 · 2019: 14 · 2018: 8 · 2017: 4 · 2016: 10 · 2015: 8 · 2014: 3 · 2013: 12 · 2012: 7
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemical Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes mellitus, duodenal mucosa, secretin, pancreatic secretion, pancreatic islets, carbohydrate metabolism, glycosuria, pancreatic hormones, acid extract
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.